If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
218
results.
Updated on
23/12/2025 [06:52:00]
Results 175 to 200 of 218
Absstract of: WO2024160936A1
The present invention provides improved RNA-LNP formulations with lower amounts of RNA adduct, As well as methods and uses to reduce the amount of RNA adduct in RNA- LNP formulations, in particular mRNA-LNP formulations.
Absstract of: CN120603581A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described; wherein the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises anions of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and RNA. Methods of making the aqueous dispersions, nucleic acid-lipid particles and methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Absstract of: CN120603581A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described; wherein the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises anions of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and RNA. Methods of making the aqueous dispersions, nucleic acid-lipid particles and methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Absstract of: CN120603581A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described; wherein the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises anions of an aqueous acid; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and RNA. Methods of making the aqueous dispersions, nucleic acid-lipid particles and methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Absstract of: WO2024161391A1
Nanoparticles comprising an outer surface covalently conjugated to 1,4-Bis(1,4,8,11-tetraazacyclotetradecan-l-yl)methylbenzene (AMD3100) or a derivative thereof capable of binding to C-X-C chemokine receptor type 4 (CXCR4) are provided. Methods for of treating a CXCR4 positive cancer, such as multiple myeloma or acute myeloid leukemia, in a subject in need thereof, methods of determining suitability for treatment and methods of covalently linking a molecule comprising a secondary amine to a lipid nanoparticle, are also provided.
Absstract of: CN121081417A
本发明提供了一种姜黄素纳米颗粒及其制备方法与应用，涉及纳米颗粒药物制备技术领域。本发明的纳米颗粒以赖氨酸为偶联剂，植物多糖为包埋璧材，姜黄素为芯材，通过自组装方法制备而成。本发明的纳米颗粒可显著提高姜黄素的包埋率和稳定性，增强其抗氧化、抗炎功效，可用于构建纳米递送体系或制备抗炎症、抗氧化功能的药物和食品，具有广泛的应用前景。
Absstract of: US2025319037A1
The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle,and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof.wherein G1 represents —C(O)—, —OC(O)—, —O(CO)O— or —C(O)O—,LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms.X represents a basic functional group.
Absstract of: CN121081623A
本发明提供一种光热纳米粒及其制备方法和用途。本发明的光热纳米粒包括聚集体纳米粒以及包覆在所述聚集体纳米粒表面的刚性层，其中，所述聚集体纳米粒由两亲性嵌段共聚物自组装形成；所述两亲性嵌段共聚物的亲油端向内聚集形成所述聚集体纳米粒的内部，所述两亲性嵌段共聚物的亲水端向外发散形成所述聚集体纳米粒的外部；且所述聚集体纳米粒的内部包含有活性分子；所述刚性层包含有氧化硅。本发明的光热纳米粒具备增强的光热转换效率，具有高效的肿瘤治疗潜力。
Absstract of: CN121081416A
本发明公开了一种靶向结肠炎的PDA@Gel@GO纳米微囊及其制备方法和应用，具体涉及一种基于半乳糖基化羧甲基壳聚糖纳米胶束口服微囊递送药物系统缓解结肠炎的研究。本申请构建了一种以Gal‑N‑CMCS为骨架、通过自组装方式负载Oridonin形成的Gal‑N‑CMCS/Oridonin（GO）纳米胶束，随后包埋入明胶微球并经多巴胺涂层制备得到的PDA@Gel@GO纳米微囊。可实现药物的口服递送和结肠靶向释放，通过抑制NLRP3炎症小体活化和促进上皮细胞再生，有效缓解DSS诱导的结肠炎症及黏膜损伤，为结肠炎的口服精准治疗提供了新的策略和机制依据。
Absstract of: CN121081376A
本发明属于生物材料技术领域，具体涉及一种纳米复合水凝胶及其制备方法和应用。所述水凝胶的制备过程中依次完成明胶酰肼化、普鲁兰多糖氧化的制备，之后完成负载活性组分的PLGA纳米颗粒制备及与金属‑多酚自组装包覆，最终金属‑多酚包覆的PLGA纳米颗粒与明胶酰肼化、普鲁兰多糖氧化混合原位成胶。该水凝胶兼具可注射、自愈合与湿黏附等特性，金属‑多酚层赋予抗炎、抗氧化和促进血管生成的作用并对近红外产生光热响应，实现对载药纳米粒的按需可控释放，该复合水凝胶能够改善创面微环境、促进血管新生并抑制炎症与瘢痕形成，适用于烧烫伤及各类复杂创面。
Absstract of: CN121081410A
本发明公开了一种HD@NitC@MOF纳米颗粒及其制备方法和应用，该制备方法包括将七水硫酸亚铁溶液与奥沙拉嗪溶液进行混合，得到混合液，将混合液在密闭条件下进行反应，得到MOF；将氯化两面针碱和MOF分别溶解于甲醇中并混合进行反应，得到NitC@MOF；向透明质酸溶液中添加EDC和NHS进行反应，再向反应液中滴加DOPA溶液进行反应，得到HA‑DOPA；将HA‑DOPA溶于去离子水中，再加入NitC@MOF进行反应制得最终产品；本发明HD@NitC@MOF对SK‑MES‑1细胞具有良好的杀伤作用，可诱导ROS的产生及GSH的消耗，并诱导SK‑MES‑1细胞发生铁死亡与坏死性凋亡，为肺鳞状细胞癌的治疗提供了新的策略。
Absstract of: CN121081423A
本发明提供一种具有高药物释放的低剂量透皮贴剂，涉及透皮贴剂技术领域。该具有高药物释放的低剂量透皮贴剂，包括背衬层、智能响应型压敏胶贮库层及防粘层，所述智能响应型压敏胶贮库层由上层速释调节层、中层缓冲过渡层和下层缓释核心层组成；所述上层速释调节层含温度敏感型促透系统，由薄荷脑、冰片与聚氧乙烯蓖麻油的复合微球构成，复合微球表面包覆聚N‑异丙基丙烯酰胺温敏涂层，当皮肤温度＞34℃时涂层溶胀加速药物释放，含量占上层总重量的5％‑20％(w/w)。通过智能响应机制提升低剂量药效，减少刺激，适应多样环境，增强靶向性，提高用药安全性与适用性。
Absstract of: CN121081418A
本发明属于纳米医学与中药领域，具体公开一种基于中药与铜离子自组装的抗氧化纳米材料及其制备方法，该纳米材料由小檗碱和原花青素B2在铜离子诱导下自组装形成的BPCu纳米颗粒，进一步通过聚乙烯吡咯烷酮进行表面修饰，得到稳定分散的PVP@BPCu纳米结构。该材料粒径小、分布均一、水溶性和储存稳定性良好，具有优异的自由基清除能力及类过氧化氢酶活性，适用于氧化应激相关疾病的辅助治疗，且本发明制备方法操作简便、无需有机溶剂，具有良好的产业化及疾病治疗潜力。
Absstract of: KR20250172233A
본 발명은 코르티코스테로이드계 약물을 포함하는 수성나노현탁겔 조성물 및 이의 용도에 관한 것으로, 본 발명에 따른 수성나노현탁겔 조성물은 고막 내, 관절 내 및 경막 외 공간에의 코르티코스테로이드 계열의 약물 전달을 증가시킴에 따라 내이질환, 관절질환 또는 뇌신경 관련 질환의 치료 효능을 증진시킬 수 있다.
Absstract of: CN121086006A
本发明公开了一种多肽修饰靶向皮肤的脂质体纳米颗粒及其制备方法和应用，所述多肽为多肽2，所述多肽2的氨基酸序列与SEQ ID NO:2至少具有80%、85%、95%、96%、97%、98%、99%及以上的同源性；所述多肽修饰靶向皮肤的脂质纳米体颗粒包括多肽2和脂质体，所述多肽与所述脂质体的质量比为（0.01~30）：100。本发明的多肽能够靶向皮肤，其与脂质体纳米颗粒混合得到了多肽修饰的脂质体纳米颗粒，该脂质体纳米颗粒能够精准实现药物分子如mRNA靶向递送至皮肤伤口部位，使其在伤口部位表达，并发挥促进伤口愈合。
Absstract of: CN121081615A
本申请涉及生物医药领域，具体公开一种RSV‑流感联合疫苗及其应用。所述RSV‑流感联合疫苗包括呼吸道合胞病毒mRNA疫苗和流感疫苗，所述呼吸道合胞病毒mRNA疫苗中还包括脂质纳米颗粒，所述mRNA装载于所述脂质纳米颗粒中。所述RSV‑流感联合疫苗用于预防多种呼吸道病毒的感染(RSV病毒和流感病毒)，并且RSV mRNA疫苗的LNP佐剂可大幅增加流感疫苗的免疫应答，增强其在免疫低下人群中的防护效率。
Absstract of: CN121087011A
本发明属于生物医药和药物制剂领域，涉及一种犬尿氨酸酶‑Fc融合蛋白、其纳米药物制剂、制备方法和应用。犬尿氨酸酶‑Fc融合蛋白由犬尿氨酸酶（KYNase）和人免疫球蛋白G的Fc结构域连接组成。相较于PEG修饰犬尿氨酸酶，犬尿氨酸酶‑Fc融合蛋白可在保持原有KYNase活性的同时，显著延长KYNase在全血中的半衰期，增加药物在肿瘤部位的浓度，提高KYNase的抗肿瘤效果。基于犬尿氨酸酶‑Fc融合蛋白的纳米药物制剂由犬尿氨酸酶‑Fc融合蛋白、光敏剂组成。该纳米药物制剂通过非共价键结合方式包载药物光敏剂，提高光敏剂在肿瘤部位富集，不改变光敏剂在全血中的半衰期。本发明提供的犬尿氨酸酶‑Fc融合蛋白可用于抗肿瘤免疫治疗，增强了肿瘤光动力治疗联合犬尿氨酸酶的免疫治疗效果。
Absstract of: CN121081429A
本发明涉及生物医药技术领域，具体涉及一种用于猪繁殖与呼吸综合征防控的可吸入式重组小RNA‑脂质纳米递送系统及其制备方法和应用。通过微流控技术将溶于有机相的脂质与溶于水相筛选得到的重组小RNA进行混合，得到具有治疗效果的重组小RNA‑脂质纳米递送系统。本发明用于猪繁殖与呼吸综合征防控的可吸入式重组小RNA‑脂质纳米递送系统，可以通过抑制猪蓝耳病病毒在细胞内复制，降低蓝耳病病毒滴度以及PRRSV蛋白水平，且脂质纳米颗粒可以稳定包封重组小RNA，为猪蓝耳病防控药物研发提供了新策略和吸入式给药的脂质纳米递送系统。
Absstract of: KR20250171518A
본 발명은 구멍갈파래를 이용한 항염·항비만 활성 탄소나노점 및 이의 제조방법에 관한 것으로서, 보다 상세하게는 버려지는 구멍갈파래를 활용하여 유기용매를 사용하지 않고 수용액 상에서 간단한 합성으로 자원 활용 및 저비용 고효율의 발광 특성을 갖는 탄소나노점을 제조하고, 상기 탄소나노점은 항염, 항비만 및 항산화 활성을 갖는 나노파티클로써 발광용 형광체 조성물, 항염, 항비만 및 항산화용 약학, 의약외품, 건강기능식품, 화장료 조성물 등 다양한 분야에서 활용 가능성이 있다.
Absstract of: AU2024255212A1
A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.
Absstract of: KR20250171513A
본 발명은 꼬불꼬시래기 추출찌꺼기를 이용한 항염·항비만 활성 탄소나노점 및 이의 제조방법에 관한 것으로서, 보다 상세하게는 버려지는 꼬불꼬시래기 추출 찌꺼기를 활용하여 유기용매를 사용하지 않고 수용액 상에서 간단한 합성으로 자원 활용 및 저비용 고효율의 발광 특성을 갖는 탄소나노점을 제조하고, 상기 탄소나노점은 항염 및 항비만 활성을 갖는 나노파티클로써 발광용 형광체 조성물, 항염 및 항비만용 약학, 의약외품, 건강기능식품, 화장료 조성물 등 다양한 분야에서 활용 가능성이 있다.
Absstract of: KR20250171981A
본 발명은 리포산 유도체 지질을 포함하는 지질 나노입자 조성물 및 이의 용도에 관한 것으로, 보다 상세하게는, 생체 친화적인 리포산 유도체 지질을 지질 나노입자를 구성하는 인지질의 대체 지질로 활용함으로써, 종래 지질 나노입자의 독성 문제를 개선함과 더불어 전달하는 mRNA가 단백질 발현을 유용하게 하고 우수한 면역 효과를 나타낼 수 있다.
Absstract of: WO2025249687A1
The present invention relates to a method for producing extracellular vesicles into which a therapeutic gene is introduced by electroporation, a wound-healing pharmaceutical composition produced by the method, and a wound-healing pharmaceutical preparation or quasi-drug preparation comprising same as an active ingredient. The extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum, produced by the present method, are all non-cytotoxic, have excellent nucleic acid delivery efficiency, and thus allow for stable expression. In particular, by introducing a vascular endothelial growth factor (VEGF) gene, which is known to have a wound-healing effect, into extracellular vesicles derived from mesenchymal stem cells (MSCs), fibroblasts, and colostrum through electroporation, VEGF gene-introduced extracellular vesicles produced by the production method of the present invention can be used as a gene therapy agent for wound healing.
Absstract of: CN121081431A
本发明公开了一种纳米复合物颗粒及其制备方法，在制备治疗癌症药物中的应用。纳米复合物颗粒，包括：由大麻二酚形成的核和包覆在所述核外部的包覆层，所述包覆层由氧化锌纳米粒子形成。通过绿色合成工艺制备ZnO纳米粒子，并进一步对其进行稀释和包封CBD，形成药物负载型ZnO/CBD复合物。通过动态光散射(DLS)测定其粒径分布，并利用Zeta电位分析其表面电荷特征，从而表征其稳定性。同时，采用透射电子显微镜(TEM)成像对所合成的ZnO/CBD进行结构分析，确认其纳米颗粒形貌及药物包封成功。制备后的ZnO/CBD复合物可用于后续的细胞实验，包括表型分析、细胞活性检测及3D球体模型观察等。
Nº publicación: CN121081664A 09/12/2025
Applicant:
四川大学华西医院
Absstract of: CN121081664A
本发明属于生物医药技术领域，具体涉及一种基于线型‑树枝状聚合物的肿瘤微环境响应型纳米药物。本发明将树枝状片段通过酶可切割的肽链连接至聚合物骨架，化疗药物通过pH不稳定性腙键偶联至树枝状外围，获得两亲性聚合物前药；通过筛选聚合单体，获得具有稳定的纳米粒，其可被肿瘤细胞高效摄取，并在肿瘤组织穿透和抗肿瘤方面具有优势；该聚合物前药还可装载腺苷受体拮抗剂药物，制得纳米药物，该纳米药物逆转腺苷介导的免疫抑制，实现腺苷受体拮抗剂药物与化疗药物的协同效应；纳米药物与PD‑1抗体协同，进一步改善了体内的免疫应答和抗TNBC的效果。本发明合成的聚合物前药和纳米药物在治疗TNBC方面前景良好。
BOPI
Electronic site
